Results 231 to 240 of about 2,190,373 (263)

A comparison of five different drug-drug interaction checkers for selective serotonin reuptake inhibitors. [PDF]

Front Pharmacol
Xu S, Song Z, Li Y, Bai J, Wang D, Wang E, Wang J.   +6 more
europepmc   +1 more source

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source

Data mining results for reduction of adverse drug-drug interaction events in older adults are clinically applicable. [PDF]

Ther Adv Drug Saf
Hunold KM, Shi Y, Zhang P, Donneyong MM, Ulintz A, Buck BH, Gordon JI, Pusateri A, Rayan M, Brownlowe K, Caterino JM.   +10 more
europepmc   +1 more source

Value of MRI Outcomes for Preventive and Early‐Stage Trials in Spinocerebellar Ataxias 1 and 3

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the value of MRI outcomes as endpoints for preventive and early‐stage trials of two polyglutamine spinocerebellar ataxias (SCAs). Methods A cohort of 100 participants (23 SCA1, 63 SCA3, median Scale for the Assessment and Rating of Ataxia (SARA) score = 5, 42% preataxic, and 14 gene‐negative controls) was scanned at 3T up ...
Thiago J. R. Rezende, Emilien Petit, Young Woo Park, Sophie Tezenas du Montcel, James M. Joers, Jonathan M. DuBois, H. Moore Arnold, Michal Povazan, Ipek Özdemir, Guita Banan, Romain Valabregue, Philipp Ehses, Jennifer Faber, Chiadi U. Onyike, Peter B. Barker, Jeremy D. Schmahmann, Eva‐Maria Ratai, Sub H. Subramony, Thomas H. Mareci, Khalaf O. Bushara, Henry Paulson, Thomas Klockgether, Alexandra Durr, Tetsuo Ashizawa, Christophe Lenglet, Gülin Öz, READISCA Investigators   +26 more
wiley   +1 more source

Assessment of Telisotuzumab Vedotin Drug-Drug Interaction Potential Using Physiologically-Based Pharmacokinetic Modeling and Simulations. [PDF]

J Clin Pharmacol
Riad MMH, Brunsdon P, Menon R, Marroum P, Parikh A.   +4 more
europepmc   +1 more source

Functional and Structural Evidence of Neurofluid Circuit Aberrations in Huntington Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Disrupted neurofluid regulation may contribute to neurodegeneration in Huntington disease (HD). Because neurofluid pathways influence waste clearance, inflammation, and the distribution of central nervous system (CNS)–delivered therapeutics, understanding their dysfunction is increasingly important as targeted treatments emerge.
Kilian Hett, Abigail Dubois, Melanie Leguizamon, Alexander Song, Paula Trujillo, Colin D. McKnight, Ciaran M. Considine, Manus J. Donahue, Daniel O. Claassen   +8 more
wiley   +1 more source

InterPAD is a database of drug-drug interaction between phytochemicals and anticancer drugs. [PDF]

Sci Rep
Zhang A, Sun X, Wu Q, Jiang H, Xu L, Gao Q, Yang Z, Zhu S, Sui X.   +8 more
europepmc   +1 more source

Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up. [PDF]

Clin Pharmacol Ther
Tremmel R, Schreeck F, Jaeger S, Schricker S, Schaeffeler E, Igel S, Steinberger D, Pagitz M, Latus J, Ketteler M, Bühl K, Dahlke MH, Kopp HG, Schwab M.   +13 more
europepmc   +1 more source

Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma. [PDF]

Clin Transl Sci
Tachibana M, Horwitz S, Jacobsen E, Foss F, Allen P, Porcu P, Feldman T, Ruan J, Brammer JE, Wang J, Inaba S, Iko Y, Nakajima K, Kakurai Y, Kitami N, Chen Y, Lau Y.   +16 more
europepmc   +1 more source

A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals. [PDF]

Eur J Clin Pharmacol
Pisanu C, Imai S, Tsuchiya M, Inoue M, Ikegami K, Zammarchi G, Kizaki H, Hori S.   +7 more
europepmc   +1 more source